 | ||||||
| "weight loss" | ||||||
| NEWS | ||||||
| Controversy Between SGLT-2 Inhibitors and GLP-1 Agonists as Preferred Second-Line Therapy Both the GLP-1 agonists and the SGLT2 inhibitors lead to a valuable HbA1c decrease and weight loss while having minimal effect on hypoglycemia. Since there are no head-to-head trials to date to compare between these two medication classes, the review of available literature has been completed ...
| ||||||
| Semaglutide Shows Superiority Over Exenatide ER in Head-to-Head Trial In addition, GLP-1 agonists slow gastric emptying, enticing the feeling of fullness longer and, therefore, lead to weight loss. Due to increased albumin binding and decreased potential to be degraded by dipeptidyl peptidase-4, a novel GLP-1 agonist semaglutide has a half-life of approximately one week.
| ||||||
| You have received this email because you have subscribed to Google Alerts. |
 Receive this alert as RSS feed |
| Send Feedback |
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.